Intravenous iron for CAPD populations: proactive or reactive strategies?

Area of Science:

• Nephrology
• Hematology
• Anemia Management

Background:

• European guidelines recommend >85% of CAPD patients achieve hemoglobin >11.0 g/dl.
• Iron deficiency is common in CAPD patients, often persisting despite oral iron therapy.
• Effective anemia management in CAPD patients is crucial for patient outcomes.

Purpose of the Study:

• To implement and evaluate an outpatient protocol for intravenous iron sucrose (IV Fe) and erythropoietin (Epo) in CAPD patients.
• To assess the impact of a proactive, integrated anemia management strategy on hemoglobin levels and guideline adherence.
• To determine if early intervention improves iron status and reduces hypochromic red blood cells in CAPD patients.

Main Methods:

• A 13-month study involving 103 CAPD patients with iron deficiency.
• Phase 1 (reactive): Oral iron converted to IV Fe (300 mg) for iron deficiency markers.
• Phase 2 (proactive): Extended criteria for IV Fe (200 mg) initiation based on ferritin and hypochromic red cells, followed by Epo therapy.

Main Results:

• Median hemoglobin increased from 11.0 to 11.7 g/dl (P=0.06).
• Absolute iron deficiency decreased from 24% to 2%.
• Percentage of hypochromic red cells significantly reduced from 4% to 1% (P<0.01).

Conclusions:

• An integrated Epo and IV Fe policy increased guideline-compliant patients from 50% to 75%.
• The protocol achieved target hemoglobin levels without increasing median Epo requirements.
• Proactive intervention is beneficial for achieving population compliance with renal anemia guidelines.